WFDC2 and ovarian carcinoma: In 2011, the FDA approved the use of serum HE4 in combination with CA125 as part of Risk of Ovarian Cancer Malignancy Algorithm (ROMA), to determine the likelihood of malignancy in women presenting with adnexal mass (49).